Site icon Patricia Prijatel

New study planned for hormone-negative therapies

Aragon Pharmaceuticals has raised $8 million to discover and develop new therapeutics for the treatment of hormone-negative cancers, with an initial focus on prostate and breast cancer.

The company has been involved in recent discoveries that show that the biology of hormone-negative cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs.

The company will focus on androgen and estrogen receptors.

Read the company’s news release here

Exit mobile version